JAMF vs NBIX · rev $627.4M vs P/E 45, rev $2.36B
Jamf Holding (JAMF) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Jamf Holding (JAMF) is a software - application company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported JAMF revenue for 2024-12-31 was $627.4M. Net income was -$68.5M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. JAMF currently screens at market cap $1.25B.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
JAMF currently screens at market cap $1.25B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the JAMF and NBIX stock pages for the full models.
Not investment advice.